Bloomberg reports that, according to the University of Oxford, the recent adverse event that prompted a suspension of the large-scale Phase 3 clinical trial evaluating COVID-19 vaccine candidate ChAdOx1 [dubbed AZD1222 by licensee AstraZeneca (AZN +0.2%)] was unlikely related to the shot.

The trial was voluntarily paused last week after a participant in the UK developed serious neurological symptoms.



Source link

Comments to: Adverse event in COVID-19 study unlikely related vaccine – Oxford (NYSE:AZN)

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.


Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.